← Leaderboards
Leonide Saad
Alkeus Pharmaceuticals, Inc.
$2,126,270
Attributed
$4,252,539
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2013–23$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
FDA$2,165,984 · 2
NIH$2,086,555 · 1
By mechanism
R01$2,165,984 · 2
R44$2,086,555 · 1
Top collaborators
- Ilyas Washington8 shared
Most similar at Alkeus Pharmaceuticals, Inc.
Same institution · by research overlap
- Ilyas Washington$6,048,568
Others in their field
Top investigators on “12 Year Old”
- Narayan Sastry · University Of Michigan At Ann Arbor$34,338,707
- Joseph Piven · Washington University$34,275,481
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$28,367,956
- Judith Kasper · Johns Hopkins University$27,775,425
- Wanda Phipatanakul · Boston Children'S Hospital$23,577,612
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$21,562,030
Research focus
12 Year OldAdultAdolescentAge Related Macular DegenerationAmericanAnimal ModelAffectAwardBioavailableBiological PreservationBlindnessCapsuleCarbonChoroidal NeovascularizationClinical DataClinical TrialsDesignDeuteriumDiagnosisDimerDimerizationDirect CostsDisabilityElderly
Grant awards (8)
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2023 · FD · contact PI
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2021 · FD · contact PI
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2019 · FD · contact PI
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$250,000
R01 · FY2018 · FD · contact PI
A Phase 2a clinical trial of ALK-001 in geographic atrophy$1,032,268
R44 · FY2017 · EY · contact PI
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$249,112
R01 · FY2017 · FD · contact PI
A Phase 2a clinical trial of ALK-001 in geographic atrophy$1,054,287
R44 · FY2016 · EY · contact PI
Phase 1 Study of ALK001 for Stargardt Disease$166,872
R01 · FY2013 · FD · contact PI